Diabetes Technology & Therapeutics

Diabetes Technology & Therapeutics is a monthly peer-reviewed journal published by Sage, established in 1999 and covering devices, drugs, delivery systems and software for the management of diabetes, with a 2025 Journal Impact Factor of 7.4 and a rank of 21st among 198 endocrinology and metabolism journals《糖尿病技术与治疗》（Diabetes Technology & Therapeutics）是由（Sage）出版的月刊，1999 年创刊，涵盖糖尿病管理所需的器械、药物、输注系统与软件，2025 年影响因子为 7.4，在 198 种内分泌与代谢期刊中列第 21 位

Scope

• Glucose monitoring is the journal's largest single subject, spanning self-monitoring, continuous glucose monitoring and data interpretation血糖监测是该刊最大的单一主题，涵盖自我监测、连续血糖监测与数据解读。
• Insulin delivery, including pumps, pens, automated insulin delivery and the artificial pancreas, is treated as an engineering as well as a clinical field胰岛素输注（含泵、笔、自动输注与人工胰腺）既被视为工程领域，也被视为临床领域。
• New insulins, adjunctive pharmacotherapy and non-insulin agents are covered with attention to how they interact with devices新型胰岛素、辅助药物治疗与非胰岛素药物均在范围内，并关注其与器械的交互。
• Software, algorithms and clinical decision support, from titration advice to closed-loop control, form a growing block of papers软件、算法与临床决策支持（从剂量调整建议到闭环控制）构成不断增长的论文板块。
• Inpatient and hospital diabetes technology, including accuracy validation for dosing decisions, has its own strand住院与院内糖尿病技术（含为给药决策而做的准确性验证）自成一脉。
• Paediatric and pregnancy applications, where device performance differs markedly from the general adult population, receive regular attention儿科与妊娠期应用受到持续关注，因为这些场景中器械表现与一般成人人群明显不同。
• Regulatory pathways, health economics and real-world evidence studies complete the applied side of the journal监管路径、卫生经济学与真实世界证据研究构成该刊的应用一侧。

History

• The journal was founded in 1999 and was published for many years by Mary Ann Liebert, building its reputation on the then-new field of diabetes devices该刊创刊于 1999 年，长期由（Mary Ann Liebert）出版，凭当时新兴的糖尿病器械领域建立声誉。
• It is now published by Sage, whose platform hosts the title and whose DOI prefix appears on articles from 2026 onwards该刊现由（Sage）出版，其平台承托该刊，2026 年起的文章使用（Sage）的 DOI 前缀。
• Twelve issues appear each year, with supplements and consensus reports accompanying the regular volume该刊每年出版 12 期，正刊之外另附增刊与共识报告。
• Publication is hybrid, with subscription access as the default and an open access option for individual articles该刊采用混合出版，默认订阅访问，单篇可选择开放获取。
• Its impact factor was 6.118 in 2021, 7.337 in 2022, 6.3 in 2024 and 7.4 in 2025, with the five-year figure now standing at 5.8其影响因子 2021 年为 6.118，2022 年为 7.337，2024 年为 6.3，2025 年为 7.4，五年影响因子现为 5.8。
• The journal is closely tied to the Advanced Technologies and Treatments for Diabetes meeting, whose consensus statements it publishes该刊与「糖尿病先进技术与治疗」会议关系紧密，并刊载该会议的共识声明。

Editors

• The editor-in-chief is Satish K. Garg of the University of Colorado Denver, based at the Barbara Davis Center for Diabetes in Aurora现任主编为（University of Colorado Denver）的（Satish K. Garg），任职于奥罗拉的（Barbara Davis Center for Diabetes）。
• David Rodbard of Biomed Informatics Consultants in Potomac, Maryland, serves as deputy editor, bringing decades of work on glucose data analysis马里兰州波托马克（Biomed Informatics Consultants）的（David Rodbard）任副编辑，带来数十年血糖数据分析工作积累。
• Roy W. Beck of the Jaeb Center for Health Research and Irl B. Hirsch of the University of Washington are senior editors, both long associated with multicentre device trials（Jaeb Center for Health Research）的（Roy W. Beck）与（University of Washington）的（Irl B. Hirsch）任高级编辑，两人长期参与多中心器械试验。
• Three associate editors cover the field, Halis K. Akturk and Gregory P. Forlenza of the Barbara Davis Center and Yogish C. Kudva of the Mayo Clinic三位副编辑覆盖该领域，即（Barbara Davis Center）的（Halis K. Akturk）与（Gregory P. Forlenza），以及（Mayo Clinic）的（Yogish C. Kudva）。
• The board of about two dozen members spans the United States, Saudi Arabia, India, Slovenia, Italy, Germany, New Zealand, Belgium, Canada, the United Kingdom, Australia and Israel约二十余人的编委会分布于美国、沙特阿拉伯、印度、斯洛文尼亚、意大利、德国、新西兰、比利时、加拿大、英国、澳大利亚与以色列。
• Janet Snell-Bergeon of the University of Colorado acts as statistical advisor, reflecting the journal's heavy reliance on quantitative device data（University of Colorado）的（Janet Snell-Bergeon）任统计顾问，反映该刊对定量器械数据的高度依赖。